The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
The antiatherogenic role of high-density lipoprotein cholesterol
Open accessAbstract
Landmark clinical studies in the past 5 years that demonstrated diminished mortality and first coronary events following lowering of low-density lipoprotein (LDL) cholesterol stimulated considerable interest in the medical community. Yet, high-density lipoprotein (HDL) cholesterol, which transports circulating cholesterol to the liver for clearance, clearly also exerts antiatherogenic effects. The Framingham Heart Study produced compelling epidemiologic evidence indicating that a low level of HDL cholesterol was an independent predictor of coronary artery disease (CAD). Emerging experimental and clinical findings are, collectively, now furnishing a solid scientific foundation for this relation. First, the reverse cholesterol transport pathway--including the roles of nascent (pre-beta) HDL, apolipoprotein A-I, lecithin-cholesterol acyltransferase (LCAT), cholesteryl ester transport protein, and hepatic uptake of cholesteryl ester from HDL by liver--is better understood. For example, the identification of a hepatic HDL receptor, SR-BI, suggests a mechanism of delivery of cholesteryl ester to liver that differs from the receptor-mediated uptake of LDL. Second, apolipoprotein A-I, the major protein component of HDL, and 2 enzymes on HDL, paraoxonase and platelet-activating factor acetylhydrolase appear to diminish the formation of the highly atherogenic oxidized LDL. Third, lower levels of HDL cholesterol are associated in a dose-response fashion with the severity and number of angiographically documented atherosclerotic coronary arteries. Fourth, low HDL cholesterol predicts total mortality in patients with CAD and desirable total cholesterol levels (<200 mg/dL). Fifth, low HDL cholesterol concentrations appear to be associated with increased rates of restenosis after percutaneous transluminal coronary angioplasty. In terms of elevating HDL cholesterol, cessation of cigarette smoking, reduction to ideal body weight, and regular aerobic exercise all appear important. Most medications used to treat dyslipidemias will raise HDL cholesterol levels modestly; however, niacin appears to have the greatest potential to do so, and can increase HDL cholesterol up to 30%. Recognizing these data, the most recent report of the National Cholesterol Education Program identified low HDL cholesterol as a CAD risk factor and recommended that all healthy adults be screened for both total cholesterol and HDL cholesterol levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Molecular physiology of reverse cholesterol transport.
Fielding, C. J., & Fielding, P. E. (1995) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39898-9 · Cited by 1,448
Probucol and Multivitamins in the Prevention of Restenosis after Coronary Angioplasty
Tardif, J.-C., Côté, G., Lespérance, J., Bourassa, M., Lambert, J., Doucet, S., Bilodeau, L., Nattel, S., & de Guise, P. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708073370601 · Cited by 565
Alderman, J. D., Pasternak, R. C., Sacks, F. M., Smith, H. S., Monrad, E. S., & Grossman, W. (1989) · The American Journal of Cardiology · doi:10.1016/0002-9149(89)90754-6 · Cited by 80
Cited by
the Tehran Lipid and Glucose Study Group, Azizi, F., Ghanbarian, A., Momenan, A. A., Hadaegh, F., Mirmiran, P., Hedayati, M., Mehrabi, Y., & Zahedi-Asl, S. (2009) · Trials · doi:10.1186/1745-6215-10-5 · Cited by 932
Endothelial and Antithrombotic Actions of HDL
Mineo, C., Deguchi, H., Griffin, J. H., & Shaul, P. W. (2006) · Circulation Research · doi:10.1161/01.res.0000225982.01988.93 · Cited by 655
Ansell, B. J., Navab, M., Hama, S., Kamranpour, N., Fonarow, G., Hough, G., Rahmani, S., Mottahedeh, R., Dave, R., Reddy, S. T., et al. (2003) · Circulation · doi:10.1161/01.cir.0000103624.14436.4b · Cited by 590
ABC1 Gene Expression and ApoA-I-Mediated Cholesterol Efflux Are Regulated by LXR
Schwartz, K., Lawn, R. M., & Wade, D. P. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3243 · Cited by 410
Navab, M., Hama, S. Y., Hough, G. P., Subbanagounder, G., Reddy, S. T., & Fogelman, A. M. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31582-0 · Cited by 334
Metadata
- Authors
- Kwiterovich, P. O.
- Venue
- The American Journal of Cardiology
- Publisher
- Elsevier BV
- Published
- 1998-11
- Volume
- 82
- Issue
- 8
- Pages
- 13-21
- ISSN
- 0002-9149 (ISSN-L)
- OpenAlex
- W2030380897
- Cited by
- 160
- References
- 7
- FWCI
- 14.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The antiatherogenic role of high-density lipoprotein cholesterol. https://app.cochat.ai/papers/10.1016/s0002-9149(98)00808-x
- The paper
- Kwiterovich, P. O. (1998). The antiatherogenic role of high-density lipoprotein cholesterol. The American Journal of Cardiology. https://doi.org/10.1016/s0002-9149(98)00808-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.